Chantix Related Published Studies
Well-designed clinical trials related to Chantix (Varenicline)
Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine
craving in adult smokers. [2015]
Effects of varenicline on smoking cessation in adults with stably treated current
or past major depression: a randomized trial. [2013]
Dissociable effect of acute varenicline on tonic versus cue-provoked craving in
non-treatment-motivated heavy smokers. [2013]
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges
among non-treatment seeking smokers. [2012]
The effects of extended pre-quit varenicline treatment on smoking behavior and
short-term abstinence: a randomized clinical trial. [2012]
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in
placebo-controlled clinical trials. [2012]
Effects of varenicline and bupropion on cognitive processes among
nicotine-deprived smokers. [2012]
Results of an initial clinical trial of varenicline for the treatment of cocaine
dependence. [2012]
Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. [2011.12]
Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. [2011.12]
The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial. [2011.11.30]
A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates. [2011.11.11]
Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial. [2011.11.02]
Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. [2011.10]
A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. [2011.09]
An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy. [2011.08.12]
Varenicline versus Bupropion XL for Smoking Cessation in Older Adolescents: A Randomized, Double-Blind Pilot Trial. [2011.07.20]
A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. [2011.06.01]
A preliminary investigation of varenicline for heavy drinking smokers. [2011.06]
Treatment of nicotine dependence with Chantix (varenicline). [2011.05]
Adherence to varenicline in the COMPASS smoking cessation intervention trial. [2011.05]
Effects of varenicline on smoking cue-triggered neural and craving responses. [2011.05]
Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. [2011.04.25]
Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. [2011.04]
Effectiveness of varenicline as an aid to smoking cessation: results of an inter-European observational study. [2011.04]
Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. [2011.04]
Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. [2011.04]
Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. [2011.03]
Gastrointestinal adverse effects of varenicline at maintenance dose: a
meta-analysis. [2011]
Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. [2010.12.06]
Immediate versus delayed quitting and rates of relapse among smokers treated successfully with varenicline, bupropion SR or placebo. [2010.11]
Effects of Varenicline on Smoking Cessation in Mild-to-Moderate COPD: A Randomized Controlled Trial. [2010.09.23]
Predictors of post-treatment relapse to smoking in successful quitters: pooled data from two phase III varenicline trials. [2010.06.01]
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. [2010.06]
Smoking outcome by psychiatric history after behavioral and varenicline treatment. [2010.06]
Behavioral counseling and varenicline treatment for smoking cessation. [2010.05]
Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. [2010.04.15]
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). [2010.04]
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). [2010.03.25]
Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. [2010.03]
The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. [2010.03]
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study. [2010.01.30]
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. [2010.01.19]
Predictors of post-treatment relapse to smoking in successful quitters: pooled
data from two phase III varenicline trials. [2010]
Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot
study. [2010]
Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. [2009.11]
Varenicline reduces alcohol self-administration in heavy-drinking smokers. [2009.07.15]
Impact of symptoms experienced by varenicline users on tobacco treatment in a real world setting. [2009.06]
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. [2009.05]
Varenicline for smoking cessation: a placebo-controlled, randomized study. [2009.04]
Varenicline for smoking cessation: A placebo-controlled, randomized study. [2009.01.23]
Varenicline improves mood and cognition during smoking abstinence. [2009.01.15]
Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. [2009.01]
Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. [2009]
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. [2008.11]
The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. [2008.07]
Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. [2008.04]
Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. [2007.11]
Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. [2007.06]
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. [2007.06]
A double-blind study evaluating the long-term safety of varenicline for smoking cessation. [2007.04]
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. [2006.12]
Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. [2006.11]
Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. [2006.11]
Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. [2006.09]
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. [2006.08.14]
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. [2006.08.14]
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. [2006.07.05]
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. [2006.07.05]
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. [2006.07.05]
Well-designed clinical trials possibly related to Chantix (Varenicline)
Culturally-tailored smoking cessation for American Indians: study protocol for a randomized controlled trial. [2011.05.18]
Utilization of services in a randomized trial testing phone- and web-based interventions for smoking cessation. [2011.05]
Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. [2011.04]
Nicotine receptor partial agonists for smoking cessation. [2011.02.16]
Interventions for smokeless tobacco use cessation. [2011.02.16]
Dianicline, a novel alpha4beta2 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial. [2011.01]
Efficacy of a flexible quit date versus an a priori quit date approach to smoking
cessation: a cross-study analysis. [2011]
Treating heavy smokers in primary care with the nicotine nasal spray: randomized
placebo-controlled trial. [2011]
Nicotine receptor partial agonists for smoking cessation. [2010.12.08]
Changes in health-related quality of life with smoking cessation treatment. [2010.09.30]
Cross-validation of a new procedure for early screening of smoking cessation medications in humans. [2010.07]
Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. [2010.06]
Working memory deficits predict short-term smoking resumption following brief abstinence. [2010.01.01]
Cross-validation of a new procedure for early screening of smoking cessation
medications in humans. [2010]
Relapse prevention interventions for smoking cessation. [2009.01.21]
Nicotine receptor partial agonists for smoking cessation. [2008.07.16]
Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. [2007.05]
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. [2007.04]
Nicotine receptor partial agonists for smoking cessation. [2007.01.24]
Other research related to Chantix (Varenicline)
Depressive symptoms among patients receiving varenicline and bupropion for
smoking cessation. [2015]
Rationale and design of a randomized controlled trial of varenicline directly
observed therapy delivered in methadone clinics. [2014]
Safety of varenicline in patients with cardiovascular disease. [2014]
A double-blind placebo-controlled randomized trial of varenicline for smokeless
tobacco dependence in India. [2014]
Combining varenicline and nicotine patches: a randomized controlled trial study
in smoking cessation. [2014]
Varenicline in the treatment of alcohol use disorders. [2014]
Safety of varenicline tartrate and counseling versus counseling alone for smoking
cessation: a randomized controlled trial for inpatients (STOP study). [2014]
The impact of pre-cessation varenicline on behavioral economic indices of smoking
reinforcement. [2014]
Combination treatment with varenicline and bupropion in an adaptive smoking
cessation paradigm. [2014]
What is the clinical effectiveness and cost-effectiveness of cytisine compared
with varenicline for smoking cessation? A systematic review and economic
evaluation. [2014]
Perceived medication assignment during a placebo-controlled laboratory study of
varenicline: temporal associations of treatment expectancies with smoking-related
outcomes. [2014]
Extended interactive voice response telephony (IVR) for relapse prevention after
smoking cessation using varenicline and IVR: a pilot study. [2013]
|